Personalized Type 2 Diabetes Management: An Update on Recent Advances and Recommendations

The Importance of Patient and Family Engagement, the Needs for Self-Monitoring of Blood Glucose (SMBG) – Our Perspectives Learned Through a Story of SMBG Assistive Devices Made by a Husband of the Patient with Diabetes

“…It has been recognized as an essential prerequisite for the successful management and treatment of diabetes in various guidelines. 1 , 7 Furthermore, with the widespread use of new self-monitoring instruments, such as isCGM, many type 1 and 2 diabetic patients and their care teams are likely to rely on isCGM as an important tool in diabetes management. 32 However, the need for continued SMBG testing reportedly remains important for all isCGM users.…”

“…There is also a recent report that the use of personalized approach in the management of T2D patients can reduce the costs and failures associated with algorithmic “one-size-fits-all” approaches, predict disease progression, improve response to diabetes medications, reduce the development of diabetes-related complications, and ultimately improve medication adherence, patient satisfaction, quality of life, diabetes distress, and physical health by using personalized approach for T2D patients. 7 These cares should be the basic principle of healthcare for patients with all chronic diseases. In addition, regarding patient decision-making, patient involvement in medical decision making is reportedly a basic principle of evidence-based medicine, and in clinical practice, it is necessary to understand the extent to which patients wish to be involved and to consider treatment options.…”

“…In addition, the importance of personalized care that takes into account the characteristics and comorbidities of each patient are important in the field of diabetes has been recently reported, as the use of personalized medicine in patients with T2D should improve medication adherence, patient satisfaction, and quality of life, reduce diabetes distress, and improve physical health. 7 …”

Editorial: Pharmacoepidemiology in Diabetes Mellitus and its Complications: Focus on Response to Medications

“…These complications can highly affect the quality of life of diabetic patients and are an extensive causal nexus for the increased burden of mortality and morbidity and treatment costs. Diabetic people with complications, on average, are charged 50–70% higher medical expenses juxtaposed to non-complicated diabetic cases ( Chan et al, 2020 ; Williams et al, 2022 ). Therefore, understanding how these medications may play a role in preventing or increasing the risk of these complications is crucial in delivering precision medicine and treatment optimization.…”

HTR1A Gene Polymorphism in Type 2 Diabetes Mellitus Comorbid with Major Depressive Disorder in a Chinese Population

“…Diabetes is a chronic metabolic disease characterized by elevated plasma glucose levels due to insulin deficiency and/or insulin function disorders. 1 The worldwide prevalence of diabetes among the adult population in 2017 was 8.8%, meaning that approximately 425 million patients had diabetes; there were 4 million deaths related to diabetes, and the medical expenses due to diabetes were estimated to be 727 billion US dollars. 2 According to the International Diabetes Federation (IDF), by 2045, the global prevalence of diabetes will increase to 9.9%, the number of patients with diabetes will reach 628.6 million, and the medical expenditures will rise to 776 billion US dollars.…”